Substitute for form 1449A/PTO INFORMATION PISCLOSURE				COMPLETE IF KNOWN		
				Application Number	10/567,249	
C!	TA TUNATENIT DV	40	RT T.C.A.N.T.	Filing Date	February 6, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Paul J. Coleman	
	10	É	/	Group Art Unit	To be determined 1624	
	(use as many sheets	A STATE OF THE PARTY OF THE PAR	ecessary)	Examiner Name	To be determined Coleman	
eet	1	of	3	Attorney Docket Number	21484P	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY
/B.C./		6,057,342		Fevig et al.	05/02/2000
/B.C./		6,440,686		Sakowicz	08/27/2002
/B.C./		3,644,414		Helsey, et al.	02/22/1972
			_		
				1	
			-		
			+		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials* Cite No. Office Number		ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
/B.C./		PCT	WO 93/20099		Yamanouchi Pharm. Co., Ltd.	10/14/1993	
/B.C./		PCT	WO 98/06694		The DuPont Merck Pharm. Co.	02/19/1998	
/B.C./		PCT	WO 03/049527		Merck & Co., Inc.	06/19/2003	
/B.C./		PCT	WO 03/105855		Merck & Co., Inc.	12/24/2003	
/B.C./		PCT	WO 2004/037171		Merck & Co., Inc.	05/06/2004	
/B.C./		PCT	WO 03/106417		Merck & Co., Inc.	12/24/2003	
/B.C./		PCT	WO 2005/019206		Merck & Co., Inc.	03/03/2005	
/B.C./		PCT	WO 2005/019205		Merck & Co., Inc.	03/03/2005	
/B.C./		EPO	EP 0 418 845		Fujisawa Pharmaceutical Co., Ltd.	08/09/1995	

Examiner Signature Date Considered /Brenda Coleman/ 03/24/2009

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MI'EP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005)

Substitute for form 1449B/PTO		COMPLETE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/567,249
STATEMENT BY APPLICANT	Filing Date	February 6, 2006
7 3/	First Named Inventor	Paul J. Coleman
JUL 3 1 2006 (P)	Group Art Unit	To be determined 1624
(133 as many sheets the necessary)	Examiner Name	To be determined Coleman
Sheet of 3	Attorney Docket Number	21484P

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/B.C./		C. Sonesson, et al., J. Org. Chem. 1996, Vol. 61, pg. 4756-4763			
/B.C./		N. Iwasawa, et al., J. Org. Chem. 1998, Vol. 63, pg. 3164-3165			
/B.C./	•	N. Iwasawa, et al., J. Org. Chem. 1997, Vol. 62, pg. 1918-1919			
/B.C./		R. Mison, et al., J. Chem. Research(S), 1989, 126-127			
** /B.C./		O. Yebdri, et al., Bulletin De La Societe Chimique de France, 1983, pg. 195-201			
** /B.C./		A. Ranjon, Bulletin De La Societe Chimique de France, 1971, pg. 2068-2072			
/B.C./		M. Bujard, et al., Tetrahedron Letters, Vol. 40, 1999, pg. 8785-8788			
/B.C./		M. Carpes, et al., Synlett, No. 7, 2000, pg. 1037-1039			
/B.C./		A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621			
/B.C./		C. Cox, et al., Bioorganic & Medicinal Chem Ltrs. Vol. 15, pgs. 2041-2045 (2005)			
/B.C./		W. Tao, Cell Cycle, Vol. 4(11), pgs. 1495-1499 (2005)			
/B.C./		K. D. Chu, et al., Proc. Am. Soc. Clin. Oncol., abstract 525, pg. 131 (2003)			
/B.C./		R. Sakowicz, et al., Cancer Research, Vol. 64, pgs. 3276-3280 (2004)			
/B.C./		W. Tao, et al., Cancer Cell, Vol. 8, pgs. 49-59 (2005)			
/B.C./		M. Fraley, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 1775-1779 (2006)			

** structures only

Examiner Signature	/Brenda Coleman/	Date Considered	03/24/2009

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005)

Substitute for form 1449B/PTO		COMPLETE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/567,249
STATEMENT BY APPRLICANT	Filing Date	February 6, 2006
/ 3\	First Named Inventor	Paul J. Coleman
(use a grany sheets as accessary)	Group Art Unit	Forberdetermined 1624
	Examiner Name	To be determined Coleman
Sheet 3 of 3	Attorney Docket Number	21484P

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
/B.C./		R. Garbaccio, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 1780-1783 (2006)				
/B.C./		C. Cox, et al., Bioorganic & Medicinal Chem Ltrs., Vol. 16, pgs. 3175-3179 (2006)				
		·				
	<u></u>					

Examiner Signature /Brenda Coleman/	Date Considered	03/24/2009
-------------------------------------	--------------------	------------

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005